Atopic dermatitis

Emerging therapies

Eric Simpson, Jeremy Udkoff, Jenna Borok, Wynnis Tom, Lisa Beck, Lawrence F. Eichenfield

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalSeminars in Cutaneous Medicine and Surgery
Volume36
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Atopic Dermatitis
United States Food and Drug Administration
Therapeutics
Cytokines
Inflammation
Skin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Simpson, E., Udkoff, J., Borok, J., Tom, W., Beck, L., & Eichenfield, L. F. (2017). Atopic dermatitis: Emerging therapies. Seminars in Cutaneous Medicine and Surgery, 36(3), 124-130. https://doi.org/10.12788/j.sder.2017.0137

Atopic dermatitis : Emerging therapies. / Simpson, Eric; Udkoff, Jeremy; Borok, Jenna; Tom, Wynnis; Beck, Lisa; Eichenfield, Lawrence F.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 36, No. 3, 01.09.2017, p. 124-130.

Research output: Contribution to journalArticle

Simpson, E, Udkoff, J, Borok, J, Tom, W, Beck, L & Eichenfield, LF 2017, 'Atopic dermatitis: Emerging therapies', Seminars in Cutaneous Medicine and Surgery, vol. 36, no. 3, pp. 124-130. https://doi.org/10.12788/j.sder.2017.0137
Simpson, Eric ; Udkoff, Jeremy ; Borok, Jenna ; Tom, Wynnis ; Beck, Lisa ; Eichenfield, Lawrence F. / Atopic dermatitis : Emerging therapies. In: Seminars in Cutaneous Medicine and Surgery. 2017 ; Vol. 36, No. 3. pp. 124-130.
@article{50e0dc30ae304cfebf22d601b5216baf,
title = "Atopic dermatitis: Emerging therapies",
abstract = "Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.",
author = "Eric Simpson and Jeremy Udkoff and Jenna Borok and Wynnis Tom and Lisa Beck and Eichenfield, {Lawrence F.}",
year = "2017",
month = "9",
day = "1",
doi = "10.12788/j.sder.2017.0137",
language = "English (US)",
volume = "36",
pages = "124--130",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Atopic dermatitis

T2 - Emerging therapies

AU - Simpson, Eric

AU - Udkoff, Jeremy

AU - Borok, Jenna

AU - Tom, Wynnis

AU - Beck, Lisa

AU - Eichenfield, Lawrence F.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

AB - Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85032834397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032834397&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2017.0137

DO - 10.12788/j.sder.2017.0137

M3 - Article

VL - 36

SP - 124

EP - 130

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 3

ER -